Equitable Trust Co. Has $6.07 Million Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Equitable Trust Co. increased its stake in Gilead by 188.4% in Q4 and now owns 49,463 shares valued at about $6.07 million.
• Company insiders have been net sellers recently — CEO Daniel O'Day sold 10,000 shares (at ~$129.16) and CFO Andrew Dickinson sold 3,000 shares (at ~$140.96), with insiders disposing of 178,640 shares worth $26.58 million in the last 90 days.
• Wall Street is broadly constructive: analysts rate GILD a "Moderate Buy" (24 Buys, 4 Holds) with an average target of $157.35, versus the stock trading around $133.48 and company FY2026 EPS guidance of 8.45–8.85.

Equitable Trust Co. increased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 188.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 49,463 shares of the biopharmaceutical company's stock after buying an additional 32,310 shares during the quarter. Equitable Trust Co.'s holdings in Gilead Sciences were worth $6,071,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in GILD. Corundum Trust Company INC acquired a new stake in Gilead Sciences during the 3rd quarter worth $26,000. Ares Financial Consulting LLC bought a new position in Gilead Sciences during the 4th quarter worth about $28,000. Financial Consulate Inc. increased its holdings in Gilead Sciences by 85.8% during the 4th quarter. Financial Consulate Inc. now owns 236 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 109 shares in the last quarter. North Star Investment Management Corp. increased its holdings in Gilead Sciences by 54.8% during the 4th quarter. North Star Investment Management Corp. now owns 243 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 86 shares in the last quarter. Finally, MTM Investment Management LLC increased its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 176 shares in the last quarter. Institutional investors and hedge funds own 83.67% of the company's stock.

Insider Activity at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction dated Tuesday, April 28th. The shares were sold at an average price of $129.16, for a total value of $1,291,600.00. Following the completion of the sale, the chief executive officer directly owned 632,567 shares in the company, valued at approximately $81,702,353.72. This trade represents a 1.56% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The shares were sold at an average price of $140.96, for a total transaction of $422,880.00. Following the completion of the sale, the chief financial officer owned 176,191 shares of the company's stock, valued at $24,835,883.36. This trade represents a 1.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 178,640 shares of company stock worth $26,584,250. Insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on GILD shares. Bank of America set a $162.00 target price on Gilead Sciences and gave the stock a "buy" rating in a report on Wednesday, February 11th. Argus increased their target price on Gilead Sciences from $135.00 to $165.00 and gave the stock a "buy" rating in a report on Thursday, February 19th. Weiss Ratings reiterated a "buy (b)" rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Rothschild & Co Redburn raised their price objective on Gilead Sciences from $159.00 to $170.00 and gave the company a "buy" rating in a report on Tuesday, February 17th. Finally, Wells Fargo & Company raised their price objective on Gilead Sciences from $150.00 to $165.00 and gave the company an "overweight" rating in a report on Wednesday, February 11th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $157.35.

Key Headlines Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: AHF says Gilead’s EPS could rise ~52% because state AIDS drug program shortfalls have increased reliance on commercial/retail supply, implying near-term revenue upside for Gilead’s HIV portfolio. Gilead's Earnings Skyrocket as Florida's AIDS Drug Program Falters, says AHF
• Positive Sentiment: Brokerage commentary and price-target coverage are constructive — a recent note cites a $157.35 target, supporting investor expectations of upside versus current levels. Brokerages Set Gilead Sciences, Inc. NASDAQ: GILD Price Target at $157.35
• Neutral Sentiment: Use of Yeztugo (twice-yearly HIV-prevention shot) is rising since launch, which supports Gilead’s growth story in prevention, but adoption is still early and incremental to overall revenues. Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain
• Neutral Sentiment: Analyst/estimate deep dives (Zacks/market write-ups) are circulating ahead of quarterly reporting; these pieces highlight key metrics investors will watch (sales mix of HIV products, hepatitis/oncology performance, and guidance). That keeps focus on fundamentals rather than a single headline. Curious about Gilead (GILD) Q1 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Brand/marketing recognition (PLAN C Impact 50) is positive for awareness but unlikely to move near-term fundamentals materially. Eight PLAN C Client Brands Named to the 3AF 2026 Impact 50
• Negative Sentiment: Insurance coverage gaps for Yeztugo remain a real constraint — patients who want the injection can face reimbursement hurdles, which could cap upside in medium-term prevention revenue if not resolved. Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Gilead Sciences Trading Up 0.6%

Shares of NASDAQ:GILD opened at $133.48 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $95.29 and a 52-week high of $157.29. The company has a market capitalization of $165.68 billion, a P/E ratio of 19.72, a price-to-earnings-growth ratio of 1.75 and a beta of 0.31. The company has a 50-day simple moving average of $140.14 and a 200 day simple moving average of $132.66. The company has a debt-to-equity ratio of 0.98, a quick ratio of 1.40 and a current ratio of 1.55.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period last year, the business posted $1.90 EPS. Gilead Sciences's revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post 8.62 earnings per share for the current year.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.